These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
833 related articles for article (PubMed ID: 35337291)
1. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma. Lai J; Xu T; Yang H BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291 [TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J Front Immunol; 2021; 12():788431. PubMed ID: 34970268 [TBL] [Abstract][Full Text] [Related]
3. Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma. Wu Y; Wang J; Ge L; Hu Q Oxid Med Cell Longev; 2022; 2022():5130648. PubMed ID: 35251475 [TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma. Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG Biochem Genet; 2024 Oct; 62(5):3439-3466. PubMed ID: 38108937 [TBL] [Abstract][Full Text] [Related]
5. Significance of Chen Y; Zhao W; Bi F; Pan X; Yin L; Zhao C Oxid Med Cell Longev; 2022; 2022():1817339. PubMed ID: 35847579 [TBL] [Abstract][Full Text] [Related]
6. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
7. A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: A TCGA data mining. Huang H; Cai X; Lin J; Wu Q; Zhang K; Lin Y; Liu B; Lin J Comput Biol Med; 2023 Mar; 155():106632. PubMed ID: 36805217 [TBL] [Abstract][Full Text] [Related]
8. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer. Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154 [TBL] [Abstract][Full Text] [Related]
9. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients. Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y Front Immunol; 2021; 12():805883. PubMed ID: 35095892 [TBL] [Abstract][Full Text] [Related]
10. An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients. Tang S; Zhuge Y Biomed Eng Online; 2021 Jun; 20(1):64. PubMed ID: 34193185 [TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an immune prognostic signature in colorectal cancer. Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948 [TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Five-immune Gene Pair Signature in Endometrial Carcinoma. Li N; Yu K; Lin Z; Zeng D Comb Chem High Throughput Screen; 2021; 24(2):233-245. PubMed ID: 32729416 [TBL] [Abstract][Full Text] [Related]
13. Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer. Qing X; Yuan C; Wang K Breast Cancer; 2023 May; 30(3):424-435. PubMed ID: 36732487 [TBL] [Abstract][Full Text] [Related]
14. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma. Li S; Dong C; Chen J; Gao X; Xie X; Zhang X Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412 [TBL] [Abstract][Full Text] [Related]
15. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer. Zhang C; Zeng C; Xiong S; Zhao Z; Wu G Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388 [TBL] [Abstract][Full Text] [Related]
16. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer. Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038 [TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Gao B; Wang Y; Lu S Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232 [TBL] [Abstract][Full Text] [Related]
18. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma. Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794 [TBL] [Abstract][Full Text] [Related]
19. Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer. Chen SF; Wang LY; Lin YS; Chen CY J Ovarian Res; 2024 Sep; 17(1):190. PubMed ID: 39342345 [TBL] [Abstract][Full Text] [Related]
20. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. Wang D; Wei G; Ma J; Cheng S; Jia L; Song X; Zhang M; Ju M; Wang L; Zhao L; Xin S BMC Cancer; 2021 May; 21(1):645. PubMed ID: 34059009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]